Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03008447 · ClinicalTrials.gov registry record · Phase 1

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

A Phase 1 study of Healthy Subjects, sponsored by Eisai.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
4
Study locations

NCT03008447: Completed Phase 1 study of Healthy Subjects, sponsored by Eisai.

NCT03008447 is a Phase 1 study of Healthy Subjects that has completed, run by Eisai. The registered enrollment target is 60 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (53% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03008447, a Phase 1 study of Healthy Subjects, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
4
Study locations

Study Summary

E2006-A001-108 is a 4-period crossover study designed to demonstrate that the mean change from baseline in postural stability (worsening) when participants are awakened at approximately 4 hours postdose is significantly less after lemborexant than after zolpidem tartrate extended release following a single-dose administration at bedtime.

Primary Outcome

Magnitude of body sway upon being awakened at approximately 4 hours after receiving lemborexant 5 milligrams (mg) (LEM5), lemborexant 10 mg (LEM10), zolpidem 6.25 mg, or placebo.

Conditions Studied

Interventions

  • DRUG LEM5
  • DRUG LEM10
  • DRUG ZOL
  • DRUG PBO

Study Locations (4)

Georgia

  • NeuroTrials Research, Inc - Atlanta

New York

  • Clinilabs, Inc - New York

North Carolina

  • Wake Research Assoicates, LLC - Raleigh

Ohio

  • Community Research Management Associates d/b/a CTI Clinical Research Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-11-21
Est. Completion 2018-01-03
Phase Phase 1
Eisai

287 total trials

What the finished NCT03008447 record still lists

NCT03008447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (53% lower).

The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 4 interventions - of which LEM5 is the first listed.

NCT03008447 reports a single indexed study location in Georgia, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03008447 about?

NCT03008447 is a clinical study titled "Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older". E2006-A001-108 is a 4-period crossover study designed to demonstrate that the mean change from baseline in postural stability (worsening) when participants are awakened at approximately 4 hours postdose is significantly less after lemborexant than after zolpidem tartrate extended release following a...

What is the current status of trial NCT03008447?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-11-21. Estimated completion is 2018-01-03.

What conditions does trial NCT03008447 study?

This clinical trial studies the following conditions: Healthy Subjects.

What interventions are being tested in trial NCT03008447?

The interventions under investigation include: LEM5 (DRUG), LEM10 (DRUG), ZOL (DRUG), PBO (DRUG).

Who is sponsoring clinical trial NCT03008447?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03008447 being conducted?

This trial has 4 study locations across Georgia, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Subjects

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03008447's enrollment target sits among peer trials

60 22nd of 69 higher than 47 of 69 other Healthy Subjects trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03008447, the US trial registry maintained by the National Library of Medicine. NCT03008447 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.